Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

Patients treated at the initial dose in an ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days

Conference Call Today at 8:30AM EST

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) in this first cohort of the study.

Patients in the first cohort received 200 mg ANA598 (n=8) or placebo (n=2), twice-daily (bid) for three days. At the end of the treatment period, the median viral load decline was 2.5 log10 (>99%), with a range of 1.4-3.4 log10, for the eight patients who received ANA598. Three patients who received ANA598 were genotype 1a and demonstrated a median viral load decline of 1.6 log10, while five patients who received ANA598 were genotype 1b and demonstrated a median viral load decline of 2.6 log10. All eight patients who received ANA598 demonstrated a rapid decline in viral load, and no patients demonstrated viral rebound while on study drug. In addition to the robust viral load decline, ANA598 was very well-tolerated and there were no serious adverse events in the first dose cohort, although conclusions regarding longer-term safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. Patients are currently being enrolled in the second cohort (400 mg bid) of the study. Anadys expects to report detailed data from multiple cohorts of the study at an upcoming medical conference.

"We are very pleased with the antiviral activity and safety of ANA598
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... N.C. , May 22, 2015  Research ... hosting its sixth Medical Affairs Roundtable ... (EDT) via a virtual roundtable to discuss "Medical ... Best Practices, Medical Affairs Consortium provides ... insights about the key challenges they face. The ...
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... , May 22, 2015  Amgen ... Company has commenced termination of its participation ... with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... is in development for patients with moderate-to-severe ... The decision was based on events of ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... 2, 2012  Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased ... the month of February, its Food and Drug Administration ... NAI (No Action Indicated) for the inspection. ... perform unannounced inspections for medical device manufacturers and the ...
... N.J., March 2, 2012 Watson Pharmaceuticals, Inc. ... Watson has launched an authorized generic version of ... part of an agreement with Abbott Laboratories. Watson ... indicated for use in the prevention of endometrial ...
Cached Medicine Technology:Solos Endoscopy, Inc. Successfully Completes Level I FDA Inspection 2Watson Launches Generic PROMETRIUM(R) 2
(Date:5/25/2015)... May 25, 2015 Thousands of ... move forward in the federal multidistrict litigation now ... Texas. According to a Motion filed on May ... modify the Case Management Order pertaining to the ... things, the Motion seeks the adoption of a ...
(Date:5/25/2015)... ProDrop Light Show allows users to ... backdrops with a click of a mouse. Users have full control ... within Final Cut Pro X. , ProDrop Light Show gives users ... kaleidoscope and much more leaving infinite possibilities all within Final Cut ... and text presets, users can apply their very own media files ...
(Date:5/25/2015)... 25, 2015 Join Fiona's Soccer Camp at ... instructional clinic. Irish National Player, Fiona O'Sullivan will be ... a taste of her coaching style. Fiona has three camps ... in Novato are at Lynwood Elmentary School (June 15-19) and ... School - June 6th, 2015 - 1:00-3:00pm. Bring a Soccer ...
(Date:5/25/2015)... 25, 2015 After the sensational buzz ... science-based human wellness company Trivedi Master Wellness™ ... their world-class series titled, “Consciousness is Power.” Presently, the ... 13, 2015 at the routinely allotted time from 10:00pm ... will be made available to the public and accessible ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2
... Beckman Coulter, Inc. (NYSE: BEC ... products that simplify, automate, and innovate complex biomedical ... vice president of strategy, will present at the ... 2009 at 11:00 a.m. (ET).(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
... cancer patients in a clinical trial were not concerned ... side effects, such as infection, pain and nausea and ... joining the clinical trial, according to a study led ... few patients reported substantial worry about drug costs, still ...
... Vitamin D intake in 3-ounce servingsMONTEREY, Calif., May 29 ... United States Department of Agriculture (USDA), Monterey Mushrooms, Inc. ... when mushrooms are exposed to light. Mushrooms respond ... the sun rays into Vitamin D. By exposing ...
... Pediatric Unit Provides Family Environment and Long-Term Care to Youth ... Center marks its 125th anniversary with the launch of ... welcomes families and simulates a home environment for long-term patients ... support that is difficult to provide in a home, group ...
... less likely than walking or running as kids age, researchers ... get older, many adolescents become less physically active and are ... a new study finds. , Researchers asked secondary school students ... five years and found that 94 percent of the students ...
... can be powerful, study says, , , FRIDAY, May 29 (HealthDay ... can help people facing the same fate make more informed ... end of their life, a new study suggests. , "Medicine ... medical care at the end of life," said the study,s ...
Cached Medicine News:Health News:1 in 10 advanced colon cancer patients worry about prescription drug costs 2Health News:Monterey Mushrooms Launches Vitamin D Enriched Sun Grill-A-Bella and White Mushrooms 2Health News:Home At HSC 2Health News:Teens Likely to Trade Team Sports for Individual Exercise 2Health News:Video May Help People Make End-of-Life Choices 2Health News:Video May Help People Make End-of-Life Choices 3
Joseph skin hook is a single end-sharp with 2 prong....
... about any contact lenses will feel good when ... four, eight or 12 hours later? Many lenses ... vision begin to look blurry. But with Proclear ... all day long., This exceptional level of comfort ...
Exceptional comfort, handling and eye health with a convenient replacement schedule. Suitable for wearers seeking the ideal combination of convenience and performance in a planned replacement soft le...
A unique lens system featuring Balanced Progressive Technology for optimum vision quality at every distance....
Medicine Products: